Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jan;33(1):128-30.
doi: 10.2337/dc09-1029. Epub 2009 Oct 6.

Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor

Dinesh Selvarajah  1 , Rajiv Gandhi, Celia J Emery, Solomon Tesfaye
Affiliations
Randomized Controlled Trial

Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor

Dinesh Selvarajah et al. Diabetes Care. 2010 Jan.

Abstract

Objective: To assess the efficacy of Sativex, a cannabis-based medicinal extract, as adjuvant treatment in painful diabetic peripheral neuropathy (DPN).

Research design and methods: In this randomized controlled trial, 30 subjects with painful DPN received daily Sativex or placebo. The primary outcome measure was change in mean daily pain scores, and secondary outcome measures included quality-of-life assessments.

Results: There was significant improvement in pain scores in both groups, but mean change between groups was not significant. There were no significant differences in secondary outcome measures. Patients with depression had significantly greater baseline pain scores that improved regardless of intervention.

Conclusions: This first-ever trial assessing the efficacy of cannabis has shown it to be no more efficacious than placebo in painful DPN. Depression was a major confounder and may have important implications for future trials on painful DPN.

PubMed Disclaimer

References

    1. Davies M, Brophy S, Williams R, Taylor A: The prevalence, severity and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 518– 522 - PubMed
    1. Bastyr EJ, 3rd, Price KL, Bril V: MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther 2005; 27: 1278– 1294 - PubMed
    1. Zigmond A, Snaith R: The hospital anxiety depression scale. Acto Psychiatr Scand 1983; 67: 361– 370 - PubMed
    1. Galer BS, Jensen MP: Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997; 48: 332– 338 - PubMed
    1. Melzack R: The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277– 299 - PubMed

Publication types